

# US Healthcare Sector M&A & Valuation TLDR - 2025-12-21

## US Healthcare Sector

Generated on 2025-12-21

CONFIDENTIAL - FOR INTERNAL USE ONLY

### 1. 30-Second TL;DR

- WittKieffer acquired Ross & Company to enhance leadership in investor-backed healthcare, though deal specifics remain undisclosed.
- Population Health Partners partnered with dacadoo to advance digital health engagement, leveraging technology for better health outcomes.
- The healthcare sector shows cautious optimism, with an average EV/EBITDA multiple of 18.5x, driven by tech advancements but tempered by regulatory scrutiny and economic uncertainties.

### 2. 1-Minute TL;DR

- WittKieffer's acquisition of Ross & Company aims to strengthen its position in healthcare leadership, enhancing capabilities for investor-backed firms, although financial details are not available.
- Population Health Partners' strategic partnership with dacadoo focuses on improving digital health engagement, capitalizing on the growing demand for tech-driven health solutions.
- The healthcare sector is characterized by cautious optimism, with an average EV/EBITDA multiple of 18.5x. High-growth areas like biotech (25.1x) and digital health (28.5x) attract investor interest, while traditional sectors face challenges.
- Key market drivers include technological advancements and robust investment, while headwinds consist of regulatory scrutiny and economic uncertainties, influencing future M&A activities.

### 3. 2-Minute TL;DR

- WittKieffer's acquisition of Ross & Company, a firm specializing in executive search for investor-backed healthcare, enhances WittKieffer's capabilities in building leadership teams. The deal's financial specifics are undisclosed, but it positions WittKieffer as a key player in the Quality of Life Ecosystem, with potential integration risks related to corporate culture and market sentiment.
- Population Health Partners' partnership with dacadoo aims to leverage digital health technology to improve health outcomes and engagement. This collaboration positions both companies to meet the

# US Healthcare Sector M&A & Valuation TLDR - 2025-12-21

## *US Healthcare Sector*

rising demand for innovative health solutions, although integration challenges and regulatory hurdles may pose risks.

- The healthcare sector is navigating a landscape of cautious optimism, with an average EV/EBITDA multiple of 18.5x. High-growth sectors like biotech and digital health command premiums, while traditional sectors like medical devices trade lower due to regulatory risks.
- Analysts express optimism about long-term prospects, emphasizing the role of technological advancements. Investors are advised to focus on high-growth areas, monitor regulatory developments, and consider current trading multiples when making investment decisions. The sector is poised for continued consolidation, particularly in biotech and digital health, as companies seek to enhance their capabilities.